Price
No data yet.
Analyst Ratings
16 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas J. Schuetz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Beta
- 0.84
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.47
Financials
Revenue
$0.00-100.0%Net Income
$-25.15MEBITDA
$-25.13MFree Cash Flow
$-13.59MEPS (diluted)
$-0.13Shares Outstanding (diluted)
186.80M+3636.0%Operating Expenses
$26.98MCash & Debt
$179.88MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-66.49M | $-0.42 |
| 2024 | $850.0K | $-49.38M | $-0.36 |
| 2023 | $0.00 | $-42.49M | $-0.33 |
| 2022 | $0.00 | $-39.23M | $-0.35 |
| 2021 | $0.00 | $-82.18M | $-1.31 |
| 2020 | $0.00 | $-29.50M | $-0.52 |
| 2019 | $0.00 | $-34.74M | $-0.67 |
| 2018 | $0.00 | $-38.29M | $-7.66 |
Valuation
CMPXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
Not enough mention history yet to chart a trend.
Earnings
Wed, Nov 4(in 6 weeks)
Consensus estimate $-0.12 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.13 vs $-0.11miss
- Tue, May 5$-0.10 vs $-0.10beat
- Thu, Mar 5$-0.09 vs $-0.10beat
- Wed, Nov 5$-0.08 vs $-0.14beat
- Mon, Aug 11$-0.14 vs $-0.13miss
- Thu, May 8$-0.12 vs $-0.12beat
Estimates and results for CMPX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CMPX officers and directors.
- Bought
- $3.2m
- Sold
- $11.5m
14 trades
5 trades
- Lerner Neilbought
- Anderman Jonathanbought
- Schuetz Thomas J.bought
- Gordon Carl Lsold
- Orbimed Advisors Llcsold
- Anderman Jonathanbought
- Lerner Neilbought
- Schuetz Thomas J.bought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CMPX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.